Enhanced In Vivo Lipid Peroxidation at Elevated Plasma Total Homocysteine Levels


Abstract—An elevated plasma total homocysteine level (tHcy) is considered an independent risk factor for atherosclerosis. The mechanisms by which hyperhomocysteinemia induces atherosclerosis are only partially understood, but promotion of LDL oxidation and endothelial injury have been suggested. The purpose of this study was to test the hypothesis that a high plasma tHcy is associated in men with increased in vivo lipid peroxidation, as measured by plasma F2-isoprostane concentrations. We investigated this association in a subset of the participants in the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study. Of 256 male participants, a subsample of 100 consecutive men was selected for F2-isoprostane assays. The mean tHcy was 11.0 μmol/L, and the mean F2-isoprostanes was 29.6 ng/L. The simple correlation coefficient for association between tHcy and F2-isoprostane was 0.40 (P<0.001). In a linear regression model, the variables with the strongest associations with F2-isoprostane were tHcy (standardized coefficient 0.33, P<0.001), serum triglycerides (0.21, P=0.042), carbohydrate-deficient transferrin (0.15, P=0.132), and plasma lipid-standardized α-tocopherol (−0.11, P=0.252) (R²=0.24, P<0.001 for model). Plasma F2-isoprostane levels increased linearly across quintiles of tHcy (P<0.001). The unadjusted mean (95% confidence interval) F2-isoprostanes was 47.5% greater in the highest tHcy quintile (37.4, 31.1 to 43.6 ng/L) than in the lowest quintile (25.3, 21.3 to 29.3 ng/L). Adjustment for the strongest other determinants of F2-isoprostane reduced this difference to 28.2% (P=0.010). Our present data suggest that elevated fasting plasma tHcy is associated with enhanced in vivo lipid peroxidation in men. (Arterioscler Thromb Vasc Biol. 1999;19:1263-1266.)

Key Words: homocysteine • F2-isoprostanes • lipid peroxidation • cardiovascular diseases

An elevated plasma total homocysteine level (referred to as tHcy), the sum of all homocysteine species in plasma, including free and protein-bound forms, has been suggested as an independent risk factor for atherosclerosis.1 Several studies have demonstrated elevated plasma tHcy levels in patients with coronary, cerebrovascular, or peripheral vascular diseases, compared with controls. This association is strong and independent of other risk factors for atherosclerosis, and it is not only limited to severe hyperhomocysteinemia but observed also when tHcy is only moderately elevated.2 The mechanisms by which hyperhomocysteinemia may induce atherogenesis are only partially understood,2 but promotion of LDL oxidation and endothelial injury have been suggested.

There is evidence from epidemiologic studies that implicates a role for lipid peroxidation in atherogenesis.3,4 Standardized methods for the assessment of lipid peroxidation in vivo have been lacking. F2-isoprostanes are a recently described class of prostaglandin-like compounds that are produced by free radical–mediated lipid peroxidation of arachidonic acid independent of cyclooxygenase.5 The quantification of F2-isoprostanes in plasma has proven to be a valuable method in assessing lipid peroxidation in vivo.6,7 Although epidemiological evidence about the association between plasma F2-isoprostanes and cardiovascular diseases is limited, increased amounts of F2-isoprostanes have been found in human atherosclerotic lesions when compared with nonatherosclerotic vessel walls.8,9 Alfthan et al10 reported an association between mean plasma tHcy concentration and mortality from cardiovascular disease (CVD) in WHO Monitoring of Trends and Determinants of Cardiovascular Disease (MONICA) data. Their data show that cross-country differences in plasma tHcy concentrations are real and not caused by noncomparable sampling and assay procedures. The correlation coefficient for plasma tHcy and CVD mortality was 0.71. The highest CVD mortality and mean plasma tHcy concentration both were observed in Finland.

The purpose of this study was to test the hypothesis that plasma tHcy concentration is associated in men with enhanced lipid peroxidation in vivo, as measured by plasma F2-isoprostane concentrations.
Enhanced Lipid Peroxidation and Elevated Homocysteine

Methods

We studied this association in a subset of the participants in the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study. The ASAP study is a balanced 2×2 factorial double-masked placebo-controlled randomized clinical trial to study the effects of vitamin C and E supplementation on oxidative stress, lipid peroxidation, atherosclerotic progression, blood pressure, and cataract formation in humans. The study protocol was approved by the Research Ethics Committee of the University of Kuopio. From 256 male participants, a subsample of 100 consecutive men were selected for F2-isoprostane assays.

For the present study, all measurements were done at the baseline visit between April and October 1995. The age of these men was 58.6±6.5 years (mean±SD), and their serum total cholesterol was 6.14±0.93 mmol/L.

Subjects were instructed to abstain from eating for 12 hours and from ingesting alcohol for a week. After a subject had rested in sitting position for 5 minutes, blood was drawn into Venoject vacuum tubes (Terumo Corp). On the day before blood drawing, a 24-hour urine was collected.

Plasma F2-isoprostane concentrations were determined at Vanderbilt University Medical Center, Nashville, Tenn, in 1997. A deuterated prostaglandin F2α internal standard was added to plasma, and F2-isoprostanes were extracted with C18 and silica minicolumns. Compounds were converted to pentafluorobenzyl ester trimethylsilyl ether derivatives and analyzed by a gas chromatographic–mass spectrometric assay. The coefficient of variation for both intraday and interday variation was 9%.

Plasma tHcy concentrations were measured at the National Public Health Institute, Helsinki, Finland, essentially as described by Araki and Sako. Homocystine, other mixed disulfides, and the protein-bound homocysteine were first released to free homocysteine by tributylphosphine, and tHcy was measured using an isocratic reversed-phase HPLC method with fluorescence detection as described earlier in detail. The coefficient of variation between series was 7%.

Plasma α-tocopherol and β-carotene were determined by HPLC, and serum lipids were quantified photometrically at the Research Institute of Public Health, Kuopio, Finland, as described earlier. Urinary nicotine metabolite 24-hour excretion was measured by a colorimetric method (Enilab). To separate the effect of α-tocopherol from that of serum lipids, values of lipid-standardized α-tocopherol were used in the statistical analysis.

The measurement of serum carbohydrate-deficient transferrin (CDT) is based on alcohol-altered glycosylation process of transferrin. Resulting transferrin is missing carbohydrate terminal chains, including sialic acid, galactose, and N-acetylgalactosamine, thus the term carbohydrate-deficient transferrin. This modified transferrin was separated by anion-exchange chromatography followed by RIA (DCTect, Pharmacia & Upjohn Diagnostics). The analyses were performed in duplicate.

The statistical significance of a linear trend in plasma F2-isoprostane over quintiles of tHcy was tested using SPSS 1-way ANOVA, with 95% confidence intervals (CI) estimated taking into account the number of tHcy categories. A stepwise linear multivariate regression analysis was used to identify the strongest other determinants of F2-isoprostane concentration. Associations between tHcy categories were adjusted with linear covariance analysis.

Results

The mean plasma tHcy was 11.0 μmol/L, and the mean of F2-isoprostanes 29.6 ng/L. The simple correlation coefficient for association between plasma tHcy and F2-isoprostane was 0.40 (P<0.001). This correlation was 0.40 (P=0.003) in 50 men whose serum total cholesterol was below the median (6.07 mmol/L) and 0.42 (P=0.003) in 50 men with a higher serum cholesterol. In a linear regression model, the variables with the strongest associations with F2-isoprostanes were tHcy (standardized coefficient 0.33, P<0.001), serum triglycerides (0.21, P=0.042), CDT (0.15, P=0.132), and plasma lipid-standardized α-tocopherol (−0.11, P=0.252) (R²=0.24, P<0.001 for model) (Table). Another most predictive variables with the plasma F2-isoprostane levels in 100 men from eastern Finland.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unadjusted Regression Coefficient</th>
<th>Adjusted Regression Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma homocysteine, μmol/L</td>
<td>0.379*</td>
<td>0.334*</td>
</tr>
<tr>
<td>Serum triglyceride, mmol/L</td>
<td>0.174</td>
<td>0.214†</td>
</tr>
<tr>
<td>Serum CDT, U/L</td>
<td>0.187</td>
<td>0.149</td>
</tr>
<tr>
<td>Plasma lipid-standardized α-tocopherol</td>
<td>−0.085</td>
<td>−0.109</td>
</tr>
<tr>
<td>Plasma β-carotene, μmol/L</td>
<td>−0.222†</td>
<td>−0.105</td>
</tr>
<tr>
<td>Urinary nicotine metabolite excretion, μmol/d</td>
<td>0.166</td>
<td>0.086</td>
</tr>
</tbody>
</table>

R² for the model (including also time of drawing the blood sample), 0.245; P=0.0002. Coefficients are standardized to SD. *P<0.001. †P<0.05.

For the present study, all measurements were done at the baseline visit between April and October 1995. The age of these men was 58.6±6.5 years (mean±SD), and their serum total cholesterol was 6.14±0.93 mmol/L.

Results

The mean plasma tHcy was 11.0 μmol/L, and the mean of F2-isoprostanes 29.6 ng/L. The simple correlation coefficient for association between plasma tHcy and F2-isoprostane was 0.40 (P<0.001). This correlation was 0.40 (P=0.003) in 50 men whose serum total cholesterol was below the median (6.07 mmol/L) and 0.42 (P=0.003) in 50 men with a higher serum cholesterol. In a linear regression model, the variables with the strongest associations with F2-isoprostanes were tHcy (standardized coefficient 0.33, P<0.001), serum triglycerides (0.21, P=0.042), CDT (0.15, P=0.132), and plasma lipid-standardized α-tocopherol (−0.11, P=0.252) (R²=0.24, P<0.001 for model) (Table). Another most predictive variables with the plasma F2-isoprostane levels in 100 men from eastern Finland.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unadjusted Regression Coefficient</th>
<th>Adjusted Regression Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma homocysteine, μmol/L</td>
<td>0.379*</td>
<td>0.334*</td>
</tr>
<tr>
<td>Serum triglyceride, mmol/L</td>
<td>0.174</td>
<td>0.214†</td>
</tr>
<tr>
<td>Serum CDT, U/L</td>
<td>0.187</td>
<td>0.149</td>
</tr>
<tr>
<td>Plasma lipid-standardized α-tocopherol</td>
<td>−0.085</td>
<td>−0.109</td>
</tr>
<tr>
<td>Plasma β-carotene, μmol/L</td>
<td>−0.222†</td>
<td>−0.105</td>
</tr>
<tr>
<td>Urinary nicotine metabolite excretion, μmol/d</td>
<td>0.166</td>
<td>0.086</td>
</tr>
</tbody>
</table>

R² for the model (including also time of drawing the blood sample), 0.245; P=0.0002. Coefficients are standardized to SD. *P<0.001. †P<0.05.

For the present study, all measurements were done at the baseline visit between April and October 1995. The age of these men was 58.6±6.5 years (mean±SD), and their serum total cholesterol was 6.14±0.93 mmol/L.

Results

The mean plasma tHcy was 11.0 μmol/L, and the mean of F2-isoprostanes 29.6 ng/L. The simple correlation coefficient for association between plasma tHcy and F2-isoprostane was 0.40 (P<0.001). This correlation was 0.40 (P=0.003) in 50 men whose serum total cholesterol was below the median (6.07 mmol/L) and 0.42 (P=0.003) in 50 men with a higher serum cholesterol. In a linear regression model, the variables with the strongest associations with F2-isoprostanes were tHcy (standardized coefficient 0.33, P<0.001), serum triglycerides (0.21, P=0.042), CDT (0.15, P=0.132), and plasma lipid-standardized α-tocopherol (−0.11, P=0.252) (R²=0.24, P<0.001 for model) (Table). Another most predictive variables with the plasma F2-isoprostane levels in 100 men from eastern Finland.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Unadjusted Regression Coefficient</th>
<th>Adjusted Regression Coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma homocysteine, μmol/L</td>
<td>0.379*</td>
<td>0.334*</td>
</tr>
<tr>
<td>Serum triglyceride, mmol/L</td>
<td>0.174</td>
<td>0.214†</td>
</tr>
<tr>
<td>Serum CDT, U/L</td>
<td>0.187</td>
<td>0.149</td>
</tr>
<tr>
<td>Plasma lipid-standardized α-tocopherol</td>
<td>−0.085</td>
<td>−0.109</td>
</tr>
<tr>
<td>Plasma β-carotene, μmol/L</td>
<td>−0.222†</td>
<td>−0.105</td>
</tr>
<tr>
<td>Urinary nicotine metabolite excretion, μmol/d</td>
<td>0.166</td>
<td>0.086</td>
</tr>
</tbody>
</table>

R² for the model (including also time of drawing the blood sample), 0.245; P=0.0002. Coefficients are standardized to SD. *P<0.001. †P<0.05.
isoprostanes were 34% greater in the high tHcy group (36.0, 31.0 to 41.0 ng/L) compared with the low tHcy group (26.8, 24.3 to 29.2 ng/L; \(P<0.001\)). Adjustment for other strongest determinants shown in the Table reduced this difference to 22.1% (\(P=0.018\)).

**Discussion**

To our knowledge, this is the first study to show that a high fasting plasma tHcy is associated with enhanced lipid peroxidation in vivo. These animals. In this study, quantification of plasma F2-isoprostanes were 34% greater in the high tHcy group (36.0, 31.0 to 41.0 ng/L) compared with the low tHcy group (26.8, 24.3 to 29.2 ng/L; \(P<0.001\)). Adjustment for other strongest determinants shown in the Table reduced this difference to 22.1% (\(P=0.018\)).

**Discussion**

To our knowledge, this is the first study to show that a high fasting plasma tHcy is associated with enhanced lipid peroxidation in vivo. These animals. In this study, quantification of plasma F2-isoprostanes were 34% greater in the high tHcy group (36.0, 31.0 to 41.0 ng/L) compared with the low tHcy group (26.8, 24.3 to 29.2 ng/L; \(P<0.001\)). Adjustment for other strongest determinants shown in the Table reduced this difference to 22.1% (\(P=0.018\)).

**Discussion**

To our knowledge, this is the first study to show that a high fasting plasma tHcy is associated with enhanced lipid peroxidation in vivo. These animals. In this study, quantification of plasma F2-isoprostanes were 34% greater in the high tHcy group (36.0, 31.0 to 41.0 ng/L) compared with the low tHcy group (26.8, 24.3 to 29.2 ng/L; \(P<0.001\)). Adjustment for other strongest determinants shown in the Table reduced this difference to 22.1% (\(P=0.018\)).

**Discussion**

To our knowledge, this is the first study to show that a high fasting plasma tHcy is associated with enhanced lipid peroxidation in vivo. These animals. In this study, quantification of plasma F2-isoprostanes were 34% greater in the high tHcy group (36.0, 31.0 to 41.0 ng/L) compared with the low tHcy group (26.8, 24.3 to 29.2 ng/L; \(P<0.001\)). Adjustment for other strongest determinants shown in the Table reduced this difference to 22.1% (\(P=0.018\)).

**References**


Enhanced In Vivo Lipid Peroxidation at Elevated Plasma Total Homocysteine Levels
Sari Voutilainen, Jason D. Morrow, L. Jackson Roberts II, Georg Alfthan, Hannu Alho,
Kristiina Nyyssönen and Jukka T. Salonen

*Arterioscler Thromb Vasc Biol* 1999;19:1263-1266
doi: 10.1161/01.ATV.19.5.1263

*Arteriosclerosis, Thrombosis, and Vascular Biology* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1999 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/19/5/1263

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Arteriosclerosis, Thrombosis, and Vascular Biology* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Arteriosclerosis, Thrombosis, and Vascular Biology* is online at:
http://atvb.ahajournals.org/subscriptions/